Chimed-Ochir O, Arachi D, Driscoll T, Lin RT, Takala J, Takahashi K. Burden of mesothelioma deaths by national income category: current status and future implications. Int J Environ Res Public Health. 2020;17(18):6900.

Article  PubMed  PubMed Central  Google Scholar 

Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92(3):587–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792–802.

Article  PubMed  Google Scholar 

Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer. 2007;43(18):2722–8.

Article  CAS  PubMed  Google Scholar 

Han J, Park S, Yon DK, Lee SW, Woo W, Dragioti E, et al. Global, regional, and national burden of mesothelioma 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019. Ann Am Thorac Soc. 2023;20(7):976–83.

Article  PubMed  Google Scholar 

Frank AL. Global use of asbestos - legitimate and illegitimate issues. J Occup Med Toxicol. 2020;15:16.

Article  PubMed  PubMed Central  Google Scholar 

WHO IAfRoC-I. Cancer tomorrow 2024 [Available from: https://gco.iarc.fr/tomorrow/en/dataviz/trends?multiple_populations=1&cancers=18.

Yoshida M, Jimbo N, Tsukamoto R, Itoh T, Kawahara K, Mitsui S, et al. Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma. Diagn Pathol. 2023;18(1):126.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sundaralingam A, Aujayeb A, Jackson KA, Pellas EI, Khan II, Chohan MT, et al. Investigation and outcomes in patients with nonspecific pleuritis: results from the International Collaborative Effusion database. ERJ Open Res. 2023;9(2):00599–2022.

Article  PubMed  PubMed Central  Google Scholar 

Bou-Samra P, Chang A, Azari F, Kennedy G, Segil A, Guo E, et al. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database. Cancer Med. 2023;12(11):12208–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carbone M, Yang H, Pass HI, Taioli E. Did the ban on asbestos reduce the incidence of mesothelioma? J Thorac Oncol. 2023;18(6):694–7.

Article  PubMed  Google Scholar 

Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–16.

Article  CAS  PubMed  Google Scholar 

Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015;75(2):264–9.

Article  CAS  PubMed  Google Scholar 

Bertuccio FR, Montini S, Fusco MA, Di Gennaro A, Sciandrone G, Agustoni F, et al. Malignant pleural mesothelioma: from pathophysiology to innovative actionable targets. Cancers (Basel). 2025;17(7):1160.

Article  CAS  PubMed  Google Scholar 

Gao Y, de Kruithof- Julio M, Peng RW, Dorn P. Organoids as a model for precision medicine in malignant pleural mesothelioma: where are we today? Cancers (Basel). 2022. https://doi.org/10.3390/cancers14153758.

Article  PubMed  PubMed Central  Google Scholar 

Zolondick AA, Gaudino G, Xue J, Pass HI, Carbone M, Yang H. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review. Precis Cancer Med. 2021;4:27.

Article  PubMed  PubMed Central  Google Scholar 

Husain AN, Chapel DB, Attanoos R, Beasley MB, Brcic L, Butnor K, et al. Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024;148(11):1251–71.

Article  CAS  PubMed  Google Scholar 

Brcic L, Kern I. Clinical significance of histologic subtyping of malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9(3):924–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin J, Yoshimura K, Sewastjanow-Silva M, Song S, Ajani JA. Challenges and prospects of patient-derived xenografts for cancer research. Cancers (Basel). 2023;15(17):4352.

Article  CAS  PubMed  Google Scholar 

Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262–5.

Article  CAS  PubMed  Google Scholar 

Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. Med. 2024;5(11):1351–77.

Article  CAS  PubMed  Google Scholar 

Fang X, Shu L, Chen T, Zhao X, Yang L, Dou T, et al. Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. Mol Cancer. 2024;23(1):12.

Article  PubMed  PubMed Central  Google Scholar 

Cong R, Lu C, Li X, Xu Z, Wang Y, Sun S. Tumor organoids in cancer medicine: from model systems to natural compound screening. Pharm Biol. 2025;63(1):89–109.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hocking AJ, Mortimer LA, Farrall AL, Russell PA, Klebe S. Establishing mesothelioma patient-derived organoid models from malignant pleural effusions. Lung Cancer. 2024;191:107542.

Article  CAS  PubMed  Google Scholar 

Luca Volpini FM, Casalone E, Herman EJ, Filomena R, Manzotti S, Strogovets O, Moroncini G, Mozzicafreddo M, Poloni A, Busilacchi EM, Gonnelli F, Barbisan F, Goteri G, Zuccatosta L, Bonifazi M, Matullo G, Neuzil J, Santarelli L, Rahman N, Blyth K, Tomasetti M, Mei F. Use of patient-derived organoids for pleural mesothelioma 3D modelling. Am J Phisiol - Lung Cell Mol Phisiol. 2025;In press.

Walz S, Pollehne P, Vollmer P, Aicher WK, Stenzl A, Harland N, et al. Effects of scaffolds on urine- and urothelial carcinoma tissue-derived organoids from bladder cancer patients. Cells. 2023;12(16):2108.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito F, Kato K, Yanatori I, Maeda Y, Murohara T, Toyokuni S. Matrigel-based organoid culture of malignant mesothelioma reproduces cisplatin sensitivity through CTR1. BMC Cancer. 2023;23(1):487.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato Y, Elbadawy M, Suzuki K, Tsunedomi R, Nagano H, Ishihara Y, et al. Establishment of an experimental model of canine malignant mesothelioma organoid culture using a three-dimensional culture method. Biomed Pharmacother. 2023;162:114651.

Article  CAS  PubMed  Google Scholar 

Xin-Yi J, Yan-Ran W, Pin-Ru D, Shi-Yi Q, Hai-Tao J. Organoids in cancer therapies: a comprehensive review. Front Bioeng Biotechnol. 2025;13:1607488.

Article  PubMed  PubMed Central  Google Scholar 

Shu D, Shen M, Li K, Han X, Li H, Tan Z, et al. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. Ann Med. 2022;54(1):2581–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito Y, Kondo J, Masuda M, Matsuzaki S, Onuma K, Kanda M, et al. Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs. Hum Cell. 2023;36(2):752–61.

Article